Fred Hassan's most recent trade in BridgeBio Pharma Inc was a trade of 8,425 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 25,889 (0%) | 0% | 0 | Common Stock | |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2025 | 87,412 | 0 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2025 | 87,412 | 1,153,452 (0%) | 0% | - | Common Stock | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 83,517 | 83,517 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 71,839 | 71,839 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 1.74 per share. | 13 Mar 2025 | 36,206 | 1,066,040 (0%) | 0% | 1.7 | 62,998 | Common Stock |
| EyePoint Pharmaceuticals Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Cocrystal Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2024 | 8,067 | 1,023,296 (2%) | 0% | - | Common Stock | |
| EyePoint Pharmaceuticals Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 60,000 | 60,000 | - | - | Stock Options (Right to buy) | |
| BridgeBio Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 101,626 | 101,626 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 87,412 | 87,412 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 14 Mar 2024 | 44,055 | 1,029,834 (0%) | 0% | 1.4 | 62,999 | Common Stock |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 106,837 | 0 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 106,837 | 985,779 (0%) | 0% | - | Common Stock | |
| Precigen Inc | Fred Hassan | Director | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 14 Aug 2023 | 570,345 | 878,942 (0%) | 0% | 1.8 | 998,104 | Common Stock |
| Cocrystal Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 7,333 | 7,333 | - | - | Stock Options (Right to Buy) | |
| BridgeBio Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 125,489 | 125,489 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 106,837 | 106,837 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 1.17 per share. | 09 Mar 2023 | 48,290 | 308,597 (0%) | 0% | 1.2 | 56,499 | Common Stock |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 61,576 | 260,307 (0%) | 0% | - | Common Stock | |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 61,576 | 0 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 16,212 | 198,731 (0%) | 0% | - | Common Stock | |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 16,212 | 0 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 83,189 | 83,189 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 61,576 | 61,576 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 2.03 per share. | 22 Feb 2022 | 27,832 | 182,519 (0%) | 0% | 2.0 | 56,499 | Common Stock |
| BridgeBio Pharma Inc | Fred Hassan | Director | Purchase of securities on an exchange or from another person at price $ 14.17 per share. | 29 Dec 2021 | 19,300 | 19,300 (0%) | 0% | 14.2 | 273,390 | Common Stock |
| BridgeBio Pharma Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 49,869 | 49,869 | - | - | Stock Option (right to buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 22,107 | 22,107 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 16,212 | 16,212 | - | - | Restricted Stock Units | |
| Precigen Inc | Fred Hassan | Director | Grant, award, or other acquisition of securities at price $ 7.71 per share. | 25 Mar 2021 | 7,328 | 154,687 (0%) | 0% | 7.7 | 56,499 | Common Stock |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2021 | 62,189 | 147,359 (0%) | 0% | - | Common Stock | |
| Precigen Inc | Fred Hassan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2021 | 62,189 | 0 | - | - | Restricted Stock Units |